BioGPU brings together Anima's molecular visualization in cells, automated cellular experiments and AI image analysis. Anima's collaborations with Lilly, Takeda and AbbVie applied its technology to discovering modulators of mRNA biology and translation. BioGPU was developed with over $150 million received through these collaborations.
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets
AbbVie (NYSE: ABBV), and Anima Biotech (Anima), announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology targets. Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie exclusive rights to license and further develop and commercialize the programs.
Anima Biotech announces strategic collaboration with Takeda to discover and develop mRNA translation modulators for Neurological diseases
Anima Biotech announced an agreement with Takeda Pharmaceutical Company Limited (“Takeda”) to discover and develop mRNA translation modulators for Neurological diseases. Under the terms of the agreement, Anima will use its Translation Control Therapeutics platform to discover novel mRNA translation modulators against the collaboration targets. The parties will collaborate to advance the molecules to clinical candidates, which Takeda has the exclusive rights to develop and commercialize. The preclinical research collaboration will initially include Anima’s early Huntington’s Disease program against the HTT target, selectively inhibiting the mutated protein with small molecules and two additional targets named by Takeda, related to neurological diseases.
Anima Biotech achieves first milestone in Takeda collaboration
The milestone relates to the Huntington’s Disease program which is part of a multi-target research collaboration between the companies. This achievement entitles Anima to an undisclosed milestone payment.
Milestone
Anima Biotech achieves milestone in Takeda collaboration
The milestone relates to one of the two newly initiated programs as part of the multi-target collaboration. This achievement entitles Anima to an undisclosed milestone payment.
Anima Biotech announces a strategic collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets
Anima Biotech announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima’s Translation Control Therapeutics platform. The multi-year agreement is structured as a strategic collaboration around several undisclosed Lilly targets. Anima will use its technology platform to discover lead candidates that are translation inhibitors of the Lilly targets. Lilly will be responsible for clinical development and commercialization of products resulting from the collaboration.
